Seaport Therapeutics reports positive GlyphAllo Phase 1 topline results
Seaport Therapeutics said it announced positive topline results from a Phase 1 Driving Simulation Trial of GlyphAllo in healthy volunteers. GlyphAllo is listed as SPT-300.
Seaport Therapeutics, Inc. (Nasdaq: SPTX) said it has reported positive topline results from the Phase 1 Driving Simulation Trial of GlyphAllo™ (SPT-300 or Glyph Allopr…).